FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - VYNE Therapeutics (NASDAQ:VYNE)

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - VYNE Therapeutics (NASDAQ:VYNE)

The U.S. Food and Drug Administration (FDA) on Friday verbally informed that it placed a clinical hold on VYNE Therapeutics Inc.’s (NASDAQ:VYNE) Phase 1b study evaluating VYN202 for the treatment of moderate-to-severe plaque psoriasis. The clinical hold determination was made following a recent observation of testicular toxicity in dogs from a non-clinical toxicology study with VYN202. VYNE has suspended all screening, enrollment, and patient do…

FDA Places Clinical Hold on VYNE’s VYN202 Phase 1b Trial for Plaque Psoriasis

VYNE Therapeutics paused its VYN202 trial for psoriasis due to an FDA-issued clinical hold.